Pegunigalsidase alfa, sold under the brand name Elfabrio, is an enzyme replacement therapy for the treatment of Fabry disease.
[2] The most common side effects are infusion-related reactions, hypersensitivity and asthenia.
[4] Pegunigalsidase alfa was approved for medical use in both the European Union and the United States in May 2023.
[4][3] Pegunigalsidase alfa is indicated for long-term enzyme replacement therapy in adults with a confirmed diagnosis of Fabry disease (deficiency of alpha-galactosidase).
[4] The applicant for this medicinal product is Chiesi Farmaceutici S.p.A.[5][6] Elfabrio was approved for medical use in the European Union in May 2023.